Barriers to accessing cellular therapy for patients receiving care in community practices.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026
   Guideline
2. Feasibility and outcomes of decentralized point-of-care CD19 CAR T cell for relapsed large B cell lymphoma in resource-limited settings.Molecular therapy. Oncology · 2026
   Article
3. Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.Blood cancer journal · 2026
   Article
4. From evidence to practice: factors influencing the implementation of cord blood treatment for cerebral palsy in the United States.Stem cells translational medicine · 2026
   Article
5. Advances and applications of engineered protein therapeutics and their role in precision medicine.Frontiers in bioengineering and biotechnology · 2026
   Review
6. Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis.Blood advances · 2025
   Article
7. Association of social vulnerability index and chimeric antigen receptor T-cell therapy administration, 2018-2023.The oncologist · 2025
   Article

Corrections and comments

• Erratum issued
  Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.2025

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.